EDAP VS FSTX Stock Comparison
Performance
EDAP10/100
10/100
EDAP returned -58.33% in the last 12 months. Based on SPY's performance of 9.73%, its performance is below average giving it a score of 10 of 100.
FSTX100/100
100/100
FSTX returned 142.18% in the last 12 months. Based on the other stocks in it's sector with an average return of -26.80%, it's performance is above average giving it a grade of 100 of 100.
Analyst Price Targets
EDAP75/100
75/100
2 analysts offer 12-month price targets for EDAP. Together, they have an average target of 0, the most optimistic target put EDAP at 0 within 12-months and the most pessimistic has EDAP at 0.
FSTX
"Analyst Price Targets" not found for FSTX
Sentiment
EDAP70/100
70/100
EDAP had a bullish sentiment score of 69.60% across Twitter and StockTwits over the last 12 months. It had an average of 2.38 posts, 2.46 comments, and 1.77 likes per day.
FSTX71/100
71/100
FSTX had a bullish sentiment score of 71.09% across Twitter and StockTwits over the last 12 months. It had an average of 9.14 posts, 1.03 comments, and 2.06 likes per day.
Technicals
EDAP14/100
14/100
EDAP receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.
FSTX86/100
86/100
FSTX receieves a 85 of 100 based on 14 indicators. 12 are bullish, 2 are bearish.
Earnings
EDAP10/100
10/100
EDAP has missed earnings 9 times in the last 20 quarters.
FSTX19/100
19/100
FSTX has missed earnings 3 times in the last 20 quarters.
Profit
EDAP42/100
42/100
Out of the last 20 quarters, EDAP has had 11 profitable quarters and has increased their profits year over year on 4 of them.
FSTX13/100
13/100
Out of the last 20 quarters, FSTX has had 2 profitable quarters and has increased their profits year over year on 2 of them.
Volatility
EDAP53/100
53/100
EDAP has had a higher than average amount of volatility over the last 12 months giving it a score of 52 of 100.
FSTX56/100
56/100
FSTX has had a higher than average amount of volatility over the last 12 months giving it a grade of 55 of 100.
All score calculations are broken down here to help you make more informed investing decisions
EDAP TMS SA Summary
Nasdaq / EDAP
Healthcare
Medical - Devices
EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment also offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; Ablatherm Fusion that incorporates the company's proprietary fusion software, which merges MRI and ultrasound images; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL division manufactures, markets, and services lithotripter for the treatment of urinary tract stones by means of ESWL technology; and offers Sonolith i-move, an extracorporeal shockwave lithotripter to small and mid-size hospitals, as well as sells disposable parts for lithotripters and electrodes. The Distribution division markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. The company markets and sells its products through its direct marketing, sales organization, and service platform, as well as through third-party distributors and agents. Its customers include hospitals, urology clinics, and research institutions. The company was incorporated in 1979 and is headquartered in Lyon, France.
F-star Therapeutics, Inc. Common Stock Summary
Nasdaq / FSTX
Healthcare
Biotechnology
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody that is in Phase 1 clinical trial targeting the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. In addition, the company is also evaluating FS120 and SB 11285 for patients with advanced cancers, which are under Phase 1 clinical trials. F-star Therapeutics, Inc. was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare EDAP to other companies in the same or a similar industry.